Nav: Home

Natural killer cells help to drive inflammation and insulin resistance

March 31, 2016

BOSTON - (March 31, 2016) - In obesity, the body's immune system can treat tissues as if they are suffering from a low-grade chronic infection. This obesity-induced inflammation is an important contributor to insulin resistance, a condition that can progress into type 2 diabetes. Researchers at Joslin Diabetes Center now have pinpointed a major inflammatory role for "natural killer" (NK) immune cells in abdominal fat--a type of tissue strongly implicated in insulin resistance.

Working in mice that were put on high-fat diets to model diabetes, "we demonstrated that obesity increases the expression of pro-inflammatory genes in abdominal fat, but not in other organs such as the liver or muscle, nor in subcutaneous fat," says Jongsoon Lee, PhD, Assistant Investigator in Joslin's Section on Pathophysiology and Molecular Pharmacology and Assistant Professor of Medicine at Harvard Medical School.

"Additionally, we showed that obesity increases the number and activity of NK cells in abdominal fat but not in other tissues," says Lee, senior author on a paper published online today in Cell Metabolism.

Working with Steven Shoelson, MD, PhD, Senior Investigator in the Section on Pathophysiology and Molecular Pharmacology and Professor of Medicine at Harvard Medical School, and other Joslin colleagues, Lee also discovered that in mice whose NK cells were removed, inflammation in abdominal fat is suppressed, and, most importantly, insulin resistance is improved. "Conversely, when we expanded the population of NK cells, we found that inflammation is increased, mainly in the abdominal fat, and insulin resistance is worsened," says Lee.

NK cells perform two main tasks for the immune system. First, as their name suggests, they kill cells that have been infected or turned cancerous. Second, NK cells churn out many different forms of signaling proteins, which can promote or suppress inflammation by aiding in recruitment and activation of other immune cells.

Lee and his colleagues believe that NK cells help to regulate insulin resistance by releasing signaling proteins that affect the behavior of macrophages, another kind of immune cells. Macrophages that appear in fat are called "adipose tissue macrophages" (ATMs) and are thought to be the major players in controlling inflammation in obesity.

The Joslin team revealed that depleting NK cells decreases the number of ATMs, suppresses pro-inflammatory ATMs and increases anti-inflammatory ATMs. Moreover, expanding NK cells reverses these effects. While many types of immune cells are involved in obesity-induced inflammation, "NK cell modulations do not change any of the other immune cells," Lee says. "As such, we have established a strong indication between NK cells and ATMs in obesity."

Thus, in discovering that NK cells control ATMS and consequently inflammation, the Joslin scientists have identified a new mechanism in the development of obesity-induced insulin resistance in mouse models.

Lee notes that manipulating these NK cells could be a promising option for potential diabetes therapies, because people with type 2 diabetes show higher numbers of NK cells in their fat tissues. Although reducing the levels of these cells could be problematic due to their role in handling infections, he explains that the immune system generally works quite differently for the regulation of insulin resistance in obesity than it does for combating infections.

Lee's team is now looking to see if cutting the generation of certain inflammation-related proteins from NK cells or ATMs can reduce inflammation and insulin resistance in obesity.
-end-
Joslin's Byung-Cheol Lee, Myung-Sunny Kim and Munkyong Pae were co-first authors on the paper. Yasuhiko Yamamoto, Delphine Eberlé, Takeshi Shimada, Nozomu Kamei, Souphatta Sasorith, Ju Rang Woo, Jia You and William Mosher also were Joslin contributors. Hee-Sook Park of Korea Food Research Institute, Korea and Hugh J. M. Brady of Imperial College in London, England were additional co-authors. Lead funding came from the American Diabetes Association and the National Institutes of Health.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

Joslin Diabetes Center

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.